With dual R&D hubs established in Beijing and Shanghai, our centres are spearheaded by over ten more senior PhDs in biotechnology and comprise a high-calibre innovation team of more than 40 scientific elites. Equipped with world-leading experimental platforms, the centres have established four major R&D systems including genetic engineering, precision fermentation, process piloting, and analytical testing. We have built a resource library of over 100,000 synthetic biological components, forming end-to-end innovation capabilities spanning molecular design to commercialisation. In core domains such as biosynthesis, cell factories, and large-scale production, SYNAURA has achieved continuous technological breakthroughs. SYNAURA has established multiple proprietary HMO core technology pathways, including 2'-FL, 3'-SL, and LNnT, with over 50 domestic and international patent applications filed to date. Through sustained research investment and innovative achievements, SYNAURA harnesses scientific prowess to drive industrial transformation, accelerating the development of a globally leading HMO innovation ecosystem.